Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Recursion Pharmaceuticals Inc Cl A (RXRX)

Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,731,312
  • Shares Outstanding, K 286,641
  • Annual Sales, $ 44,580 K
  • Annual Income, $ -328,070 K
  • EBIT $ -394 M
  • EBITDA $ -370 M
  • 60-Month Beta 0.81
  • Price/Sales 40.32
  • Price/Cash Flow N/A
  • Price/Book 3.42

Options Overview Details

View History
  • Implied Volatility 167.22% ( +69.70%)
  • Historical Volatility 71.79%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 167.22% on 11/21/24
  • IV Low 67.98% on 09/24/24
  • Put/Call Vol Ratio 0.14
  • Today's Volume 9,218
  • Volume Avg (30-Day) 8,150
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 160,252
  • Open Int (30-Day) 135,290

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.35
  • Number of Estimates 3
  • High Estimate -0.29
  • Low Estimate -0.42
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.62 +2.85%
on 11/21/24
8.49 -31.92%
on 11/11/24
-0.98 (-14.50%)
since 10/21/24
3-Month
5.62 +2.85%
on 11/21/24
8.49 -31.92%
on 11/11/24
-1.84 (-24.15%)
since 08/21/24
52-Week
5.62 +2.85%
on 11/21/24
15.74 -63.28%
on 02/27/24
-0.76 (-11.62%)
since 11/21/23

Most Recent Stories

More News
Recursion Completes Merger with Exscientia, Launches Comprehensive AI-Enabled Drug Discovery Portfolio

Recursion announces post-combination technology portfolio with over 30 drug programs, aiming to enhance AI-driven drug discovery efficiency.Quiver AI SummaryRecursion has announced the completion of its...

RXRX : 5.79 (-4.14%)
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

RXRX : 5.79 (-4.14%)
Recursion and Exscientia Shareholders Approve the Proposed Combination

RXRX : 5.79 (-4.14%)
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

RXRX : 5.79 (-4.14%)
Inside the AI-Healthcare Boom: Breakthroughs in Diagnostics and Personalized Treatment

Issued on behalf of Avant Technologies Inc. VANCOUVER – USA News Group News Commentary – A recent World Economic Forum report highlights AI's potential to ease the strain on healthcare systems...

MSFT : 415.67 (+0.24%)
NVDA : 145.04 (-0.58%)
TWST : 42.36 (+3.04%)
AVAI : 0.5525 (+6.25%)
ABSI : 2.67 (-0.37%)
RXRX : 5.79 (-4.14%)
EXAI : 4.84 (+3.20%)
Recursion Pharmaceuticals: Q3 Earnings Snapshot

Recursion Pharmaceuticals: Q3 Earnings Snapshot

RXRX : 5.79 (-4.14%)
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

RXRX : 5.79 (-4.14%)
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?

In an environment where the typical small biotech name is riskier than not, this one is curiously different.

RXRX : 5.79 (-4.14%)
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

RXRX : 5.79 (-4.14%)
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock

This company stands to benefit from a shifting pharmaceutical industry landscape.

RXRX : 5.79 (-4.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 7.04
2nd Resistance Point 6.71
1st Resistance Point 6.37
Last Price 5.79
1st Support Level 5.70
2nd Support Level 5.37
3rd Support Level 5.03

See More

52-Week High 15.74
Fibonacci 61.8% 11.87
Fibonacci 50% 10.68
Fibonacci 38.2% 9.49
Last Price 5.79
52-Week Low 5.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar